Cargando…

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review

Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Bencina, Goran, Petrova, Elina, Sönmez, Demet, Matos Pereira, Sonia, Dimitriadis, Ioannis, Salomonsson, Stina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290826/
https://www.ncbi.nlm.nih.gov/pubmed/37366384
http://dx.doi.org/10.36469/001c.75208
_version_ 1785062572479741952
author Bencina, Goran
Petrova, Elina
Sönmez, Demet
Matos Pereira, Sonia
Dimitriadis, Ioannis
Salomonsson, Stina
author_facet Bencina, Goran
Petrova, Elina
Sönmez, Demet
Matos Pereira, Sonia
Dimitriadis, Ioannis
Salomonsson, Stina
author_sort Bencina, Goran
collection PubMed
description Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and nonmetastatic castration-resistant prostate cancer. To improve decision-making regarding the value of anticancer therapies and support standardized assessment for use by health technology assessment (HTA) agencies, the European Society for Medical Oncology (ESMO) has developed a Magnitude of Clinical Benefit Scale (MCBS). Objective: This review aimed to map HTA status, reimbursement restrictions, and patient access for 3 advanced prostate cancer indications across 23 European countries during 2011-2021. Methods: HTA, country reimbursement lists, and ESMO-MCBS scorecards were reviewed for evidence and data across 26 European countries. Results: The analysis demonstrated that only in Greece, Germany, and Sweden was there full access across all included prostate cancer treatments. Treatments available for metastatic castration-resistant prostate cancer were widely reimbursed, with both abiraterone and enzalutamide accessible in all countries. In 3 countries (Hungary, the Netherlands, and Switzerland), there was a statistically significant difference (P<.05) between status of reimbursement and ESMO-MCBS “substantial benefit” (score of 4 or 5) vs “no substantial benefit” (score <4). Conclusion: Overall, the impact of the ESMO-MCBS on reimbursement decisions in Europe is unclear, with significant variation across the countries included in this review.
format Online
Article
Text
id pubmed-10290826
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Columbia Data Analytics, LLC
record_format MEDLINE/PubMed
spelling pubmed-102908262023-06-26 HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review Bencina, Goran Petrova, Elina Sönmez, Demet Matos Pereira, Sonia Dimitriadis, Ioannis Salomonsson, Stina J Health Econ Outcomes Res Oncology Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and nonmetastatic castration-resistant prostate cancer. To improve decision-making regarding the value of anticancer therapies and support standardized assessment for use by health technology assessment (HTA) agencies, the European Society for Medical Oncology (ESMO) has developed a Magnitude of Clinical Benefit Scale (MCBS). Objective: This review aimed to map HTA status, reimbursement restrictions, and patient access for 3 advanced prostate cancer indications across 23 European countries during 2011-2021. Methods: HTA, country reimbursement lists, and ESMO-MCBS scorecards were reviewed for evidence and data across 26 European countries. Results: The analysis demonstrated that only in Greece, Germany, and Sweden was there full access across all included prostate cancer treatments. Treatments available for metastatic castration-resistant prostate cancer were widely reimbursed, with both abiraterone and enzalutamide accessible in all countries. In 3 countries (Hungary, the Netherlands, and Switzerland), there was a statistically significant difference (P<.05) between status of reimbursement and ESMO-MCBS “substantial benefit” (score of 4 or 5) vs “no substantial benefit” (score <4). Conclusion: Overall, the impact of the ESMO-MCBS on reimbursement decisions in Europe is unclear, with significant variation across the countries included in this review. Columbia Data Analytics, LLC 2023-06-20 /pmc/articles/PMC10290826/ /pubmed/37366384 http://dx.doi.org/10.36469/001c.75208 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Bencina, Goran
Petrova, Elina
Sönmez, Demet
Matos Pereira, Sonia
Dimitriadis, Ioannis
Salomonsson, Stina
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
title HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
title_full HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
title_fullStr HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
title_full_unstemmed HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
title_short HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
title_sort hta and reimbursement status of metastatic hormone‑sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer treatments in europe: a patient access landscape review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290826/
https://www.ncbi.nlm.nih.gov/pubmed/37366384
http://dx.doi.org/10.36469/001c.75208
work_keys_str_mv AT bencinagoran htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview
AT petrovaelina htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview
AT sonmezdemet htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview
AT matospereirasonia htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview
AT dimitriadisioannis htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview
AT salomonssonstina htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview